Myriad Genetics, Personalis enter agreement to cross-license patent estates

Myriad Genetics (MYGN) and Personalis (PSNL) announced that they have entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The agreement helps solidify each company’s freedom to operate in the MRD market and broadens patient access to the benefits of MRD testing. “Myriad and Personalis are each working to re-define the standard for MRD testing and increasing market access to better inform clinical decision making for the treatment and monitoring of oncology patients,” said Paul J. Diaz, President and CEO, Myriad Genetics. “We believe that our unique sets of capabilities and inclusive approach to using intellectual property for the benefit of patients will help drive broader MRD testing adoption, reimbursement, and greatly advance this opportunity for patients in this emerging and under-penetrated market. Myriad’s Precise MRD is a tumor-informed, genome-scale MRD test that is part of Precise Oncology Solutions, our expanding portfolio of comprehensive molecular diagnostic tools for oncology detection and treatment.”